Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2003

View Archived Issues

F-13640 produces antiallodynic activity in rat model of trigeminal neuropathic pain

Renoprotective effects of magnesium lithospermate B in diabetic OLETF rats

Erlosamide reported to reduce the frequency of partial seizures

Therapeutic benefits described for ropinirole in RLS

Long-term use of antimuscarinic drugs increases senile plaque density in older PD patients

Inhibition of vasopeptidase with AVE-7688 reduces kidney damage in ZDF rats

Intravitreous hyaluronidase effective in reducing vitreous hemorrhage density

Good efficacy and safety profile described for ranibizumab in AMD

Prolonged pharmacokinetic profile reported for the novel GLP-1 analogue CJC-1131

Genesis Bioventures and Corgenix Medical to merge

Intravenous Nexium to be launched in Sweden

Full approval for Serostim in AIDS wasting

HepeX-B granted orphan drug status

Novel CDK inhibitors described in recent Warner-Lambert patent

Ajinomoto claims new acetyl-CoA carboxylase inhibitors for obesity, diabetes, etc.

New TAFI inhibitors for thrombotic disorders under evaluation at Pfizer

Bayer researchers describe two novel series of Rho kinase inhibitors

New agents for thrombopenia therapy in early development at Yamanouchi

Valtrex approved for reducing risk of spreading genital herpes

Chemically novel inhibitor of GSK3 with potential in type 2 diabetes

New Zonegran dosage strengths approved

Therapeutic utility of BIM-51077 in diabetes investigated in ZDF rats

Subsidy supports development of ex vivo IL-10 gene therapy for Crohn's disease

European approval obtained for Actos

Mechanism of action of CKD-501, a new thiazolidinedione derivative

Candesartan reported to reduce mortality and morbidity in symptomatic heart failure

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026